SPECTRUM PHARMS
SpecialtySPECTRUM PHARMS is a specialty pharmaceutical company focused on Oncology, Infectious Disease.
FDA Novel Drug Designations
(2022)See 1 novel approval →
SPECTRUM PHARMS at a Glance
- Fast trial execution (28 months median completion)
SPECTRUM PHARMS's Key Drugs
SPECTRUM PHARMS's core commercial portfolio centers on ROLVEDON, spanning Oncology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
SPECTRUM PHARMS's Recent FDA Approvals
New NDA/BLA approvals for SPECTRUM PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
SPECTRUM PHARMS's Therapeutic Areas
SPECTRUM PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Infectious Disease, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SPECTRUM PHARMS's Top Competitors
SPECTRUM PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SPECTRUM PHARMS Pipeline Snapshot
Active clinical trials for SPECTRUM PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ROLVEDON leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/11 completed
- • Speed: 28 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1962-04-25
- Latest
- 2025-12-12
- Applications
- 5
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges